Drug Profile
Research programme: cancer therapeutics - Kamat Pharmatech
Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Kamat Pharmatech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Sep 2023 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Powder)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Suspension)